secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001193125-23-270898
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 2.01, 2.02, 3.02, 3.03, 4.01, 5.01, 5.02, 5.03, 5.05, 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Frequency closes reverse merger with Korro Bio; combined entity renamed Korro Bio, Inc.
--------------------------------------------------------------------------------

- Legacy Korro stockholders own ~91% of combined company; pre-closing financing raised $117.3M at ~$2.78/share.
- 1-for-50 reverse stock split effective Nov 3, 2023; ~738,526 pre-split shares became ~8.0M post-Merger shares outstanding.
- New CEO Ram Aiyar; board reconstituted with 6 directors; Nessan Bermingham appointed Chair.
- Auditor changed from RSM US LLP to Ernst & Young LLP; CVR agreement created for MS program asset proceeds.
- Common stock begins trading on Nasdaq Capital Market under KRRO on Nov 6, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/0001193125-23-270898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-270898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer